New Alzheimer's drug OLX-07010 enters first human safety trial

NCT ID NCT05696483

Ongoing Disease control Sponsor: Oligomerix, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This Phase 1 study tests the safety of OLX-07010, a drug designed to stop tau proteins from clumping in the brain—a hallmark of Alzheimer's disease. Researchers will give single or multiple doses to 88 healthy adults and elderly volunteers to see how the body handles the drug and if it causes side effects. This is the first time OLX-07010 is being tested in humans, so the main goal is safety, not effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OLX-07010 (a tau self-association inhibitor)
What this could lead to: If successful, this early study could pave the way for a treatment that slows Alzheimer's by preventing tau protein clumps in the brain.
What could go wrong: This is a very early Phase 1 safety trial in healthy people, not patients. It is too soon to know if OLX-07010 will work for Alzheimer's, and many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

California Clinical Trials Medical Group, Inc

Glendale, California, 91206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.